Avalo Therapeutics pays off remaining $35 million Horizon debt

By Marisa Wong

Los Angeles, Sept. 26 – Avalo Therapeutics announced it paid off the remainder of its $35 million debt owed to Horizon Technology Finance Corp.

The company said this significant milestone not only signifies its steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug candidates, including its anti-Light mAb (quisovalimab or AVTX-002) and its BTLA agonist fusion protein (AVTX-008).

Avalo is a Rockville, Md.-based clinical stage biotechnology company focused on the treatment of immune dysregulation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.